EIKON THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
EIKON THERAPEUTICS, INC. (EIKN) reported Capital Expenditures Incurred but Not yet Paid of $102.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-13
- EIKON THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$119.00K.
- EIKON THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $221.00K, a 97.64% decline year-over-year.
- EIKON THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$9.07M.
- EIKON THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $9.35M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month |
|---|---|---|
| 2026-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $102.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $221.00K 10-Q · filed 2026-05-11 | |
| 2025-06-30 | -$9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $279.00K 10-Q · filed 2026-08-13 |
| 2025-03-31 | $9.35M 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |